This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsGenerix（GENX）株式概要Generix SA develops SaaS based supply chain solutions worldwide. 詳細GENX ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長1/6過去の実績2/6財務の健全性5/6配当金0/6報酬収益は年間6.37%増加すると予測されています リスク分析過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見るGENX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€9.70該当なし内在価値ディスカウントEst. Revenue$PastFuture-179k115m2016201920222025202620282031Revenue €115.1mEarnings €4.6mAdvancedSet Fair ValueView all narrativesGenerix SA 競合他社SidetradeSymbol: ENXTPA:ALBFRMarket cap: €242.6mLinedata ServicesSymbol: ENXTPA:LINMarket cap: €220.7mStreamwideSymbol: ENXTPA:ALSTWMarket cap: €219.0mESI GroupSymbol: ENXTPA:ESIMarket cap: €879.8m価格と性能株価の高値、安値、推移の概要Generix過去の株価現在の株価€9.7052週高値€10.0052週安値€5.20ベータ0.451ヶ月の変化0.21%3ヶ月変化1.04%1年変化1.04%3年間の変化95.96%5年間の変化304.17%IPOからの変化-97.66%最新ニュースRecent Insider Transactions • Jul 27Insider recently bought €70k worth of stockOn the 22nd of July, Jean-Luc Barma bought around 7k shares on-market at roughly €9.58 per share. In the last 3 months, they made an even bigger purchase worth €79k. Insiders have collectively bought €223k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jul 08Insider recently bought €79k worth of stockOn the 1st of July, Jean-Luc Barma bought around 8k shares on-market at roughly €9.56 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Jun 10Full year 2022 earnings: Revenues in line with analyst expectationsFull year 2022 results: Revenue: €84.5m (up 5.3% from FY 2021). Net income: €3.40m (down 32% from FY 2021). Profit margin: 4.0% (down from 6.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.5%, compared to a 12% growth forecast for the industry in France.分析記事 • Apr 29Returns On Capital Are Showing Encouraging Signs At Generix (EPA:GENX)What are the early trends we should look for to identify a stock that could multiply in value over the long term...分析記事 • Mar 30A Look At The Fair Value Of Generix SA (EPA:GENX)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Generix SA ( EPA:GENX...Buying Opportunity • Mar 07Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 41%. The fair value is estimated to be €7.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% per annum over the last 3 years. Earnings per share has grown by 41% per annum over the last 3 years.最新情報をもっと見るRecent updatesRecent Insider Transactions • Jul 27Insider recently bought €70k worth of stockOn the 22nd of July, Jean-Luc Barma bought around 7k shares on-market at roughly €9.58 per share. In the last 3 months, they made an even bigger purchase worth €79k. Insiders have collectively bought €223k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jul 08Insider recently bought €79k worth of stockOn the 1st of July, Jean-Luc Barma bought around 8k shares on-market at roughly €9.56 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Jun 10Full year 2022 earnings: Revenues in line with analyst expectationsFull year 2022 results: Revenue: €84.5m (up 5.3% from FY 2021). Net income: €3.40m (down 32% from FY 2021). Profit margin: 4.0% (down from 6.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.5%, compared to a 12% growth forecast for the industry in France.分析記事 • Apr 29Returns On Capital Are Showing Encouraging Signs At Generix (EPA:GENX)What are the early trends we should look for to identify a stock that could multiply in value over the long term...分析記事 • Mar 30A Look At The Fair Value Of Generix SA (EPA:GENX)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Generix SA ( EPA:GENX...Buying Opportunity • Mar 07Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 41%. The fair value is estimated to be €7.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% per annum over the last 3 years. Earnings per share has grown by 41% per annum over the last 3 years.Valuation Update With 7 Day Price Move • Mar 01Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €6.22, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 29x in the Software industry in France. Total returns to shareholders of 61% over the past three years.お知らせ • Dec 10Generix Group Provides Revenue Guidance for Fiscal Year 2021Generix Group provided revenue guidance for fiscal year 2021. For the year, the company expects its revenue growth to be a few points lower than the double-digit growth previously expected, but nevertheless higher than the pre-crisis revenue for fiscal 2019-2020.Major Estimate Revision • Jun 10Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.19 to €0.24. Revenue forecast unchanged at €88.0m. Net income forecast to grow 6.0% next year vs 24% growth forecast for Software industry in France. Consensus price target up from €8.50 to €9.00. Share price was steady at €9.36 over the past week.Reported Earnings • Jun 05Full year 2021 earnings releasedThe company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: €80.3m (down 1.0% from FY 2020). Net income: €5.00m (up 47% from FY 2020). Profit margin: 6.2% (up from 4.2% in FY 2020).Price Target Changed • Jun 03Price target increased to €9.00Up from €8.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of €9.32. Stock is up 43% over the past year.分析記事 • May 04Generix (EPA:GENX) Has More To Do To Multiply In Value Going ForwardIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...分析記事 • Mar 08What Kind Of Investors Own Most Of Generix SA (EPA:GENX)?Every investor in Generix SA ( EPA:GENX ) should be aware of the most powerful shareholder groups. Institutions will...分析記事 • Feb 15Is Generix's (EPA:GENX) 194% Share Price Increase Well Justified?When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...分析記事 • Jan 27Does Generix (EPA:GENX) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Jan 13New 90-day high: €8.06The company is up 6.0% from its price of €7.60 on 14 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Software industry, which is up 5.0% over the same period.分析記事 • Jan 09Here's What To Make Of Generix's (EPA:GENX) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Dec 22Does Generix's (EPA:GENX) Statutory Profit Adequately Reflect Its Underlying Profit?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...Reported Earnings • Dec 12First half 2021 earnings released: EPS €0.09The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €38.1m (down 4.4% from 1H 2020). Net income: €2.05m (down 43% from 1H 2020). Profit margin: 5.4% (down from 8.9% in 1H 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.Analyst Estimate Surprise Post Earnings • Dec 12Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 2.7%, compared to a 7.9% growth forecast for the Software industry in France.分析記事 • Dec 07Could The Market Be Wrong About Generix SA (EPA:GENX) Given Its Attractive Financial Prospects?With its stock down 6.6% over the past three months, it is easy to disregard Generix (EPA:GENX). But if you pay close...分析記事 • Nov 19What Is Generix SA's (EPA:GENX) Share Price Doing?Generix SA (EPA:GENX), is not the largest company out there, but it saw significant share price movement during recent...Valuation Update With 7 Day Price Move • Nov 02Market pulls back on stock over the past weekAfter last week's 17% share price decline to €6.52, the stock is trading at a trailing P/E ratio of 42.8x, down from the previous P/E ratio of 51.5x. This compares to an average P/E of 64x in the Software industry in France. Total returns to shareholders over the past three years are 129%.Valuation Update With 7 Day Price Move • Oct 29Market pulls back on stock over the past weekAfter last week's 16% share price decline to €6.56, the stock is trading at a trailing P/E ratio of 43.1x, down from the previous P/E ratio of 51.2x. This compares to an average P/E of 64x in the Software industry in France. Total returns to shareholders over the past three years are 129%.Is New 90 Day High Low • Oct 26New 90-day high: €7.84The company is up 9.0% from its price of €7.22 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is flat over the same period.株主還元GENXFR SoftwareFR 市場7D0%-6.2%-0.4%1Y1.0%-41.2%2.2%株主還元を見る業界別リターン: GENX過去 1 年間で-41.2 % の収益を上げたFrench Software業界を上回りました。リターン対市場: GENX過去 1 年間で2.2 % の収益を上げたFrench市場を上回りました。価格変動Is GENX's price volatile compared to industry and market?GENX volatilityGENX Average Weekly Movement1.1%Software Industry Average Movement6.7%Market Average Movement5.5%10% most volatile stocks in FR Market11.0%10% least volatile stocks in FR Market2.9%安定した株価: GENX 、 French市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: GENXの 週次ボラティリティ は、過去 1 年間で7%から1%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト1990787Aida Senewww.generixgroup.comもっと見るGenerix SA 基礎のまとめGenerix の収益と売上を時価総額と比較するとどうか。GENX 基礎統計学時価総額€219.96m収益（TTM）€3.41m売上高(TTM)€84.50m64.5xPER（株価収益率2.6xP/SレシオGENX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GENX 損益計算書（TTM）収益€84.50m売上原価€68.77m売上総利益€15.74mその他の費用€12.32m収益€3.41m直近の収益報告Mar 31, 2022次回決算日該当なし一株当たり利益（EPS）0.15グロス・マージン18.62%純利益率4.04%有利子負債／自己資本比率32.0%GENX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/09/13 06:34終値2022/08/23 00:00収益2022/03/31年間収益2022/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Generix SA 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Jean Pascal BrivadyCIC Market Solutions (ESN)Emmanuel MatotODDO BHF Corporate & MarketsMatthias DesmaraisODDO BHF Corporate & Markets1 その他のアナリストを表示
Recent Insider Transactions • Jul 27Insider recently bought €70k worth of stockOn the 22nd of July, Jean-Luc Barma bought around 7k shares on-market at roughly €9.58 per share. In the last 3 months, they made an even bigger purchase worth €79k. Insiders have collectively bought €223k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jul 08Insider recently bought €79k worth of stockOn the 1st of July, Jean-Luc Barma bought around 8k shares on-market at roughly €9.56 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Jun 10Full year 2022 earnings: Revenues in line with analyst expectationsFull year 2022 results: Revenue: €84.5m (up 5.3% from FY 2021). Net income: €3.40m (down 32% from FY 2021). Profit margin: 4.0% (down from 6.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.5%, compared to a 12% growth forecast for the industry in France.
分析記事 • Apr 29Returns On Capital Are Showing Encouraging Signs At Generix (EPA:GENX)What are the early trends we should look for to identify a stock that could multiply in value over the long term...
分析記事 • Mar 30A Look At The Fair Value Of Generix SA (EPA:GENX)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Generix SA ( EPA:GENX...
Buying Opportunity • Mar 07Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 41%. The fair value is estimated to be €7.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% per annum over the last 3 years. Earnings per share has grown by 41% per annum over the last 3 years.
Recent Insider Transactions • Jul 27Insider recently bought €70k worth of stockOn the 22nd of July, Jean-Luc Barma bought around 7k shares on-market at roughly €9.58 per share. In the last 3 months, they made an even bigger purchase worth €79k. Insiders have collectively bought €223k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jul 08Insider recently bought €79k worth of stockOn the 1st of July, Jean-Luc Barma bought around 8k shares on-market at roughly €9.56 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Jun 10Full year 2022 earnings: Revenues in line with analyst expectationsFull year 2022 results: Revenue: €84.5m (up 5.3% from FY 2021). Net income: €3.40m (down 32% from FY 2021). Profit margin: 4.0% (down from 6.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.5%, compared to a 12% growth forecast for the industry in France.
分析記事 • Apr 29Returns On Capital Are Showing Encouraging Signs At Generix (EPA:GENX)What are the early trends we should look for to identify a stock that could multiply in value over the long term...
分析記事 • Mar 30A Look At The Fair Value Of Generix SA (EPA:GENX)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Generix SA ( EPA:GENX...
Buying Opportunity • Mar 07Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 41%. The fair value is estimated to be €7.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% per annum over the last 3 years. Earnings per share has grown by 41% per annum over the last 3 years.
Valuation Update With 7 Day Price Move • Mar 01Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €6.22, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 29x in the Software industry in France. Total returns to shareholders of 61% over the past three years.
お知らせ • Dec 10Generix Group Provides Revenue Guidance for Fiscal Year 2021Generix Group provided revenue guidance for fiscal year 2021. For the year, the company expects its revenue growth to be a few points lower than the double-digit growth previously expected, but nevertheless higher than the pre-crisis revenue for fiscal 2019-2020.
Major Estimate Revision • Jun 10Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.19 to €0.24. Revenue forecast unchanged at €88.0m. Net income forecast to grow 6.0% next year vs 24% growth forecast for Software industry in France. Consensus price target up from €8.50 to €9.00. Share price was steady at €9.36 over the past week.
Reported Earnings • Jun 05Full year 2021 earnings releasedThe company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: €80.3m (down 1.0% from FY 2020). Net income: €5.00m (up 47% from FY 2020). Profit margin: 6.2% (up from 4.2% in FY 2020).
Price Target Changed • Jun 03Price target increased to €9.00Up from €8.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of €9.32. Stock is up 43% over the past year.
分析記事 • May 04Generix (EPA:GENX) Has More To Do To Multiply In Value Going ForwardIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
分析記事 • Mar 08What Kind Of Investors Own Most Of Generix SA (EPA:GENX)?Every investor in Generix SA ( EPA:GENX ) should be aware of the most powerful shareholder groups. Institutions will...
分析記事 • Feb 15Is Generix's (EPA:GENX) 194% Share Price Increase Well Justified?When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
分析記事 • Jan 27Does Generix (EPA:GENX) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Jan 13New 90-day high: €8.06The company is up 6.0% from its price of €7.60 on 14 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Software industry, which is up 5.0% over the same period.
分析記事 • Jan 09Here's What To Make Of Generix's (EPA:GENX) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Dec 22Does Generix's (EPA:GENX) Statutory Profit Adequately Reflect Its Underlying Profit?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Reported Earnings • Dec 12First half 2021 earnings released: EPS €0.09The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €38.1m (down 4.4% from 1H 2020). Net income: €2.05m (down 43% from 1H 2020). Profit margin: 5.4% (down from 8.9% in 1H 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
Analyst Estimate Surprise Post Earnings • Dec 12Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 2.7%, compared to a 7.9% growth forecast for the Software industry in France.
分析記事 • Dec 07Could The Market Be Wrong About Generix SA (EPA:GENX) Given Its Attractive Financial Prospects?With its stock down 6.6% over the past three months, it is easy to disregard Generix (EPA:GENX). But if you pay close...
分析記事 • Nov 19What Is Generix SA's (EPA:GENX) Share Price Doing?Generix SA (EPA:GENX), is not the largest company out there, but it saw significant share price movement during recent...
Valuation Update With 7 Day Price Move • Nov 02Market pulls back on stock over the past weekAfter last week's 17% share price decline to €6.52, the stock is trading at a trailing P/E ratio of 42.8x, down from the previous P/E ratio of 51.5x. This compares to an average P/E of 64x in the Software industry in France. Total returns to shareholders over the past three years are 129%.
Valuation Update With 7 Day Price Move • Oct 29Market pulls back on stock over the past weekAfter last week's 16% share price decline to €6.56, the stock is trading at a trailing P/E ratio of 43.1x, down from the previous P/E ratio of 51.2x. This compares to an average P/E of 64x in the Software industry in France. Total returns to shareholders over the past three years are 129%.
Is New 90 Day High Low • Oct 26New 90-day high: €7.84The company is up 9.0% from its price of €7.22 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is flat over the same period.
